Results 41 to 50 of about 9,990,963 (401)

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2021
Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis.
M. Tempero, M. Malafa, M. Al-Hawary, S. Behrman, A. Benson, D. Cardin, E. Chiorean, V. Chung, B. Czito, M. Del Chiaro, M. Dillhoff, T. Donahue, E. Dotan, C. Ferrone, Christos Fountzilas, J. Hardacre, W. Hawkins, Kelsey A Klute, A. Ko, J. Kunstman, N. Loconte, A. Lowy, C. Moravek, E. Nakakura, A. Narang, Jorge V. Obando, Patricio M. Polanco, S. Reddy, M. Reyngold, C. Scaife, Jeanne Shen, C. Vollmer, R. Wolff, B. Wolpin, B. Lynn, Giby V. George   +35 more
semanticscholar   +1 more source

LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability

Journal of Translational Medicine, 2023
Background LIPH, a membrane-associated phosphatidic acid-selective phospholipase A1a, can produce LPA (Lysophosphatidic acid) from PA (Phosphatidic acid) on the outer leaflet of the plasma membrane.
Lijie Han, Yongsheng Jiang, Minmin Shi, Lina Gan, Zhichong Wu, Meilin Xue, Youwei Zhu, Cheng Xiong, Ting Wang, Xiaozhu Lin, Baiyong Shen, Lingxi Jiang, Hao Chen   +12 more
doaj   +1 more source

Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability

Journal for ImmunoTherapy of Cancer, 2023
Background Solid tumors pose unique roadblocks to treatment with chimeric antigen receptor (CAR) T cells, including limited T-cell persistence, inefficient tumor infiltration, and an immunosuppressive tumor microenvironment. To date, attempts to overcome
Qi Zhang, Jiangchao Wu, Tingbo Liang, Xueli Bai, Xun Wang, Jianpeng Sheng, Junlei Zhang, Jianghui Tang, Jinyuan Song, Yongtao Ji   +9 more
doaj   +1 more source

Tumors in von Hippel–Lindau Syndrome: From Head to Toe—Comprehensive State-of-the-Art Review [PDF]

, 2018
Von Hippel–Lindau syndrome (VHL) is an autosomal-dominant hereditary tumor disease that arises owing to germline mutations in the VHL gene, located on the short arm of chromosome 3.
Bhalla, Sanjeev, Ganeshan, Dhakshinamoorthy, Lubner, Meghan G., Menias, Christine O., Pickhardt, Perry J., Ramalingam, Preetha, Sandrasegaran, Kumaresan   +6 more
core   +1 more source

STUDIES IN PANCREATIC DISEASE [PDF]

Archives of Internal Medicine, 1915
PART I.—DUODENAL CONTENT ANALYSES AS AN INDEX OF DISEASE, AND FUNCTIONAL ACTIVITY OF THE PANCREAS A reliable method for ascertaining the functional activity of the pancreas, has been eagerly sought for the last few decades, in fact since the time that Kuntzman, Richard Bright and Claude Bernard first called attention to this gland as a possible focus ...
openaire   +3 more sources

Pancreatic Cancer: Pathogenesis, Screening, Diagnosis and Treatment.

Gastroenterology, 2022
Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our understanding of the biology of PDAC have revealed new opportunities ...
L. Wood, M. Canto, E. Jaffee, D. Simeone
semanticscholar   +1 more source

Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection

World Journal of Surgical Oncology, 2021
Background Elevated plasma D-dimer levels have been reported as an unfavorable prognostic indicator in many solid tumors. However, there are limited relevant studies in pancreatic cancer patients following radical surgery, and the clinical significance ...
Haoda Chen, Fanlu Li, Siyi Zou, Junjie Xie, Jun Zhang, Xiaxing Deng, Hao Chen, Baiyong Shen   +7 more
doaj   +1 more source

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. [PDF]

, 2018
BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer.
Bedford, Rudolph, Donahue, Timothy, Hines, O Joe, Hoos, William, Isacoff, William H, Rahib, Lola, Reber, Howard A, Upfill-Brown, Alexander   +7 more
core   +1 more source

Pancreatic Cancer: A Review of Current Treatment and Novel Therapies.

Journal of investigative surgery, 2022
Pancreatic cancer is one of the leading causes for cancer-related deaths in the United States. Majority of patients present with unresectable or metastatic disease.
H. Kolbeinsson, S. Chandana, G. Wright, M. Chung   +3 more
semanticscholar   +1 more source

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? [PDF]

, 2003
Background: Serial kinetics of serum CA 19-9 levels have been reported to reflect response and survival in patients with pancreatic cancer undergoing surgery, radiotherapy, and chemotherapy.
Garbrecht, M., Heinemann, Volker, Helmberger, T., Lamerz, Rolf, Niebler, K., Schalhorn, A., Schermuly, M. M., Stemmler, J., Stieber, P., Stoffregen, C., Szymala, A. M., Wilkowski, R.   +11 more
core   +1 more source